

1 **COVID-19 Antibody in Thai Community Hospitals**

2 Tanawin Nopsopon, M.D.

3 Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

4 tropsopon@gmail.com

5

6 Krit Pongpirul, M.D., M.P.H., Ph.D. (Corresponding Author)

7 Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok,

8 Thailand; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore,

9 MD, USA; Bumrungrad International Hospital, Bangkok, Thailand

10 doctorkrit@gmail.com

11

12 Narin Hiransuthikul, M.D., Ph.D.

13 Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

14 narin.h@chula.ac.th

15

16 Words: 1,299 words (Text), 206 words (Abstract)

17 **Abstract**

18 **Background**

19 COVID-19 seroprevalence data has been scarce, especially in less developed countries with a relatively low
20 infection rate.

21 **Methods**

22 A locally developed rapid IgM/IgG test kit was used for screening hospital staff and patients who required
23 procedural treatment or surgery in 33 hospitals in Thailand from April 8 to June 8, 2020. A total of 587 participants
24 were tested—459 were hospital staff and 128 were pre-procedural patients. (Thai Clinical Trials Registry:
25 TCTR20200426002)

26 **Results**

27 Overall, 3.4% of the participants (20 of 587) had positive immunoglobulin M (IgM) and none had positive
28 immunoglobulin G. Hospitals located in the central part of Thailand had the highest IgM seroprevalence (7.4%).
29 Preprocedural patients had a higher rate of positive IgM than the hospital staff (7.0% vs. 2.4%). Participants with
30 present upper respiratory tract symptoms had a higher rate of positive IgM than those without (5.9% vs. 2.7%).
31 Three quarter (77%, 452 of 587) of the participants were asymptomatic, of which, twelve had positive IgM (2.7%)
32 which consisted of 7 of 369 healthcare workers (1.9%) and 5 of 83 preprocedural patients (6.0%).

33 **Conclusions**

34 COVID-19 antibody test could detect a substantial number of potential silent spreaders in Thai community hospitals.
35 Antibody testing should be encouraged for mass screening, especially in asymptomatic individuals.

36 **Introduction**

37 Polymerase chain reaction (PCR) was introduced as a diagnostic test of choice for coronavirus disease 2019
38 (COVID-19) infection. However, it might not be readily available or affordable in many facilities and could pose an
39 unnecessary risk to the healthcare providers during the specimen collection. Besides, a recent study raised a concern
40 of false-negative result from PCR test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in
41 patients with high pretest probability and encouraged the development of a highly sensitive test [1]. In Thailand, the
42 PCR test was offered in suspected individuals with strict criteria during the initial phase of the COVID-19
43 pandemic. As a more feasible, cheaper, and safer alternative to the PCR, the antibody test is not only useful for an
44 epidemiological investigation [2] but could also be used for mass screening of potential silent spreaders—
45 asymptomatic COVID-19 individuals.

46 Hospital is one of the best venues for getting and spreading pathogens. In community hospitals in Thailand,
47 there are two types of people who potentially are silent spreaders and need antibody testing: (1) healthcare workers
48 who have a relatively higher risk of infection than laypersons, and (2) asymptomatic patients who need procedural
49 treatment or operation but do not meet the criteria for PCR testing.

50 **Methods**

51 From 8th April 2020 to 8th June 2020, hospital staff and patients who needed procedural treatment or operation but
52 did not meet the national PCR testing criteria in 244 hospitals (215 community hospitals and 29 general hospitals)
53 from all regions of Thailand were offered antibody testing. Of 215 community hospitals, only data from 33 hospitals
54 (15.3%) were readily available and complete while none of the data from general hospitals was timely and
55 sufficient. Patients with PCR confirmed COVID-19 infection were quarantined and excluded. Baiya Rapid COVID-
56 19 IgG/IgM test kit (Baiya Phytopharm, Thailand) which reports the presence of immunoglobulin M (IgM) and
57 immunoglobulin G (IgG) qualitatively, was used in this study. The internal validation of the test kit using the serum
58 of 51 PCR confirmed COVID-19 cases and 150 controls showed sensitivity 94.1% (48 of 51) and specificity 98.0%
59 (147 of 150) for IgM or IgG antibody.

60 **Statistical analysis**

61 Categorical data were presented with counts and percentages while continuous data were provided with median and
62 interquartile range. The 95% confidence interval (CI) of the seroprevalence was calculated by Wilson's method

63 using binomial probabilities. Missing data were excluded. A two-tailed $p < 0.05$ was considered statistically
64 significant. All data were analyzed using Stata 16.1 (College Station, TX).


65 Ethics Committee Approval

66 This study was approved by the Institutional Review Board of Chulalongkorn University (IRB No.236/63) and other
67 18 hospitals. (Thai Clinical Trials Registry: TCTR20200426002)

68 **Results**

69 From 33 community hospitals, 587 participants which consisted of 459 hospital staff and 128 pre-procedural
70 patients were included in the study. Their median age was 36 years (interquartile range 28–45), 73.4% were female,
71 99.0% were Thai, and 77.0% were asymptomatic. The most common symptoms were cough (11.9%), sore throat
72 (8.0%), rhinitis (7.8%), fever (6.1%) and dyspnea (3.6%). History of travel to the high-risk area was 5.8%, history of
73 close contact to the confirmed COVID-19 case was 16.7%, and 12.3% had PCR negative.

74 Twenty participants (3.4%, 95% CI 2.2–5.2) had IgM antibody against SARS-CoV-2 whereas IgG antibody was not
75 found in any participant. Participants from the Central region of Thailand had the highest IgM seroprevalence (7.4%,
76 95% CI 4.0–13.0), while the Northern and Southern region showed zero seroprevalences [Fig 1].



77

78 **Fig 1.** IgM seroprevalence in community hospitals across geographical regions of Thailand.

79 Pre-procedural patients had an unexpectedly higher proportion of positive IgM than the hospital staff (7.0%
80 vs. 2.4%), especially patients in the central region of Thailand (14.7%, 95% CI 6.4–30.1). Overall, the seropositive
81 prevalence was higher in female (3.9% vs. 2.1%), participants with a history of travel to the high-risk area (5.9% vs.
82 3.3%), with history of close contact to confirmed COVID-19 case (6.1% vs. 2.9%). Paradoxically, patients without
83 travel history were likely to have an antibody for SARS-CoV-2 (7.8% vs. 3.8%). In general, participants with upper
84 respiratory tract symptoms had a higher chance of being seropositive (5.9% vs. 2.7%), of which sore throat had the
85 highest (10.6%, 95% CI 4.6–22.6). Also, pre-procedural patient with sore throat had the most IgM positive (20.0%,
86 95% CI 7.0–45.2) while the symptom was dyspnea for healthcare worker (33.3%, 95% CI 6.1–79.2). Of 452
87 participants without present upper respiratory tract symptom, twelve had IgM positive for COVID-19 (2.7%, 95%
88 CI 1.5–4.6) which consisted of 7 of 369 healthcare workers (1.9%, 95% CI 0.9–3.9) and 5 of 83 patients (6.0%, 95%

89 CI 2.6–13.3). History of negative PCR was associated with a lower chance of seropositive than those with no PCR
 90 test result (1.4% vs. 3.7%) [Table 1].

91 **Table 1.** Demographic characteristics and seroprevalence in different groups

	All participant		Healthcare worker		Pre-procedural patient	
	n	IgM+	n	IgM+	n	IgM+
Total	587	20 (3.4%)	459	11 (2.4%)	128	9 (7.0%)
Median age, year (25th, 75th percentile)	36 (28–45)		36 (28–44)		36.5 (25–54)	
Male, n (%)	140 (23.9%)	3 (2.1%)	92 (20.0%)	1 (1.1%)	48 (37.5%)	2 (4.2%)
Female, n (%)	438 (74.6%)	17 (3.9%)	358 (78.0%)	10 (2.8%)	80 (62.5%)	7 (8.8%)
Unspecified, n (%)	9 (1.5%)	0 (0.0%)	9 (2.0%)	0 (0.0%)	0 (0.0%)	0 (NA)
Thai	581	20 (3.4%)	455	11 (2.4%)	126	9 (7.1%)
Non-Thai	6	0 (0.0%)	4	0 (0.0%)	2	0 (0.0%)
Region						
North	18	0 (0.0%)	18	0 (0.0%)	0	0 (NA)
Northeast	182	3 (1.6%)	154	0 (0.0%)	28	3 (10.7%)
Central	136	10 (7.4%)	102	5 (4.9%)	34	5 (14.7%)
South	80	0 (0.0%)	60	0 (0.0%)	20	0 (0.0%)
East	171	7 (4.1%)	125	6 (4.8%)	46	1 (2.2%)
History of travel to high risk area						
Yes	34	2 (5.9%)	8	1 (12.5%)	26	1 (3.8%)
No	553	18 (3.3%)	451	10 (2.2%)	102	8 (7.8%)
History of close contact confirmed case						
Yes	98	6 (6.1%)	88	5 (5.7%)	10	1 (10.0%)
No	489	14 (2.9%)	371	3 (0.8%)	118	8 (6.8%)
Asymptomatic	452	12 (2.7%)	369	7 (1.9%)	83	5 (6.0%)
Symptomatic	135	8 (5.9%)	90	4 (4.4%)	45	4 (8.9%)
Fever	36	3 (8.3%)	14	0 (0.0%)	22	3 (13.6%)
Cough	70	3 (4.3%)	47	1 (2.1%)	23	2 (8.7%)
Rhinitis	46	3 (6.5%)	34	2 (5.9%)	12	1 (8.3%)
Sore throat	47	5 (10.6%)	32	2 (6.3%)	15	3 (20.0%)
Dyspnea	21	2 (9.5%)	3	1 (33.3%)	18	1 (5.6%)
Previous PCR status						
Negative	72	1 (1.4%)	42	1 (2.4%)	30	0 (0.0%)
Never tested	515	19 (3.7%)	417	10 (2.4%)	98	9 (9.2%)

92 Data were presented in counts and percentages, unless otherwise specified.
 93 IgM+, immunoglobulin M positive; NA, not available; PCR, polymerase chain reaction.

94 Discussion

95 COVID-19 seroprevalence in asymptomatic staff and patients in Thai community hospitals was comparable to
 96 hospitals in China (2.7% vs. 2.5%) [3]. Seroprevalence in asymptomatic hospital staff in Thailand was also similar
 97 to hospitals in China (1.9% vs. 1.8%) [3] but less than a tertiary hospital in Belgium (1.9% vs. 6.4%) [4].
 98 Asymptomatic patients in Thailand seemed to have higher seroprevalence than China (6.0% vs. 3.5%) [3]. Unlike
 99 China and Belgium where the seroprevalences were mostly from positive IgG, our study revealed only positive IgM.
 100 Comparison with Belgium hospital should be interpreted with caution due to unknown PCR status of Belgium
 101 subjects.

102 Limitations

103 Limitations of this study include the use of locally developed test kit, lack of IgG-positive participants which might

104 be from early testing and exclusion of PCR positive COVID-19 patients which might underestimate real
105 seroprevalence.

106 **Conclusions**

107 COVID-19 antibody test could detect a substantial number of potential silent spreaders in Thai community hospitals.

108 Antibody testing should be encouraged for mass screening, especially in asymptomatic individuals.

109 **Acknowledgements**

110 We thank Baiya Phytopharm, Thailand for supporting the Baiya Rapid COVID-19 IgG/IgM test kit. The company
111 did not involve in the data analysis, interpretation, and the manuscript preparation.

112 **Author Contributions**

113 **Conceptualization:** TN, KP, NH

114 **Data curation:** TN, KP

115 **Formal analysis:** TN, KP

116 **Investigation:** TN, KP

117 **Methodology:** TN, KP, NH

118 **Project administration:** TN, KP, NH

119 **Resources:** KP, NH

120 **Software:** TN, KP

121 **Supervision:** KP, NH

122 **Validation:** TN, KP

123 **Visualization:** TN

124 **Writing – original draft:** TN, KP

125 **Writing – review & editing:** TN, KP, NH

126 **References**

- 127 1. Woloshin S, Patel N, Kesselheim A. False Negative Tests for SARS-CoV-2 Infection - Challenges and
128 Implications. *N Engl J Med*. 2020. Epub 2020/06/06. doi: 10.1056/NEJMp2015897. PubMed PMID: 32502334.
- 129 2. Yong S, Anderson D, Wei W, Pang J, Chia W, Tan C, et al. Connecting clusters of COVID-19: an
130 epidemiological and serological investigation. *Lancet Infect Dis*. 2020. Epub 2020/04/25. doi: 10.1016/s1473-
131 3099(20)30273-5. PubMed PMID: 32330439; PubMed Central PMCID: PMC7173813.
- 132 3. Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies
133 against SARS-CoV-2 in China. *Nat Med*. 2020. Epub 2020/06/07. doi: 10.1038/s41591-020-0949-6. PubMed
134 PMID: 32504052.
- 135 4. Steensels D, Oris E, Coninx L, Nuyens D, Delforge M, Vermeersch P, et al. Hospital-Wide SARS-CoV-2
136 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. *Jama*. 2020. Epub 2020/06/17. doi:
137 10.1001/jama.2020.11160. PubMed PMID: 32539107.

138